论文部分内容阅读
目的 了解紫杉醇联合顺铂化疗方案在晚期食道癌治疗中的临床应用以及其能达到临床治疗效果,为食道癌患者制订合理临床治疗方案提供依据.方法 选取79例病历资料完整的晚期食道癌患者,随机分为实验组40例和对照组39例,对照组给予5-氟尿嘧啶联合顺铂化疗,实验组给予紫杉醇联合顺铂化疗方案,分析比较两治疗组患者在临床治疗效果、不良反应发生以及生存时间方面的变化情况.结果 紫杉醇联合顺铂治疗组患者的生存时间要比5-氟尿嘧啶联合顺铂治疗组患者长.结论 食道癌晚期患者经紫杉醇联合顺铂化疗后能够取得较为明显的治疗效果,能够延长患者的生存时间,且不良反应情况较5-氟尿嘧啶联合顺铂化疗方案来的少,值得在临床上推广使用.
Objective To understand the clinical application of paclitaxel combined with cisplatin chemotherapy in the treatment of advanced esophageal cancer and its clinical therapeutic effect and to provide a basis for rational clinical treatment of esophageal cancer patients.Methods A total of 79 patients with advanced esophageal cancer were selected, Randomly divided into experimental group of 40 cases and control group of 39 cases, the control group was given 5 - fluorouracil combined with cisplatin chemotherapy, paclitaxel combined with cisplatin in the experimental group chemotherapy regimen, analysis of two treatment groups in patients with clinical treatment, adverse reactions and survival Time change.Results The survival time of patients treated with paclitaxel combined with cisplatin was longer than that of patients treated with 5-fluorouracil combined with cisplatin.Conclusion The treatment of patients with advanced esophageal cancer by paclitaxel combined with cisplatin can obtain more significant therapeutic effect, Can prolong the survival time of patients, and adverse reactions than 5-fluorouracil combined with cisplatin less chemotherapy program, it is worth to promote the clinical use.